Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
Exploring Personal Stem Cell Banking within Regenerative Medicine: A Conversation with Kevin Ferber, COO of American Cell Technology
*Sponsored Content: The article is sponsored by HEALInc Global Summit.
As the world of healthcare continues to evolve, regenerative medicine is emerging as a cornerstone of personalized, proactive health. In line with the mission of the 2025 HEALinc Global Summit – which aims to restore whole-person health through cutting-edge technologies, mentorship and education – the potential of stem cell therapy is poised to redefine our approach to health, longevity and wellness. Founded in 2018 by Dr. Desirée Cox (MD, MPhil, PhD), the HEALinc Global Summit brings together leaders and innovators to explore the latest scientific breakthroughs in healthy longevity and regenerative medicine. This year’s Summit will be held at the Atlantis Resort in The Bahamas from April 27th – 29th, 2025. [Read more…]
Sernova Advances Cell Pouch Type I Diabetes Trial; Will Test iPSC-Derived Clusters Next
-
Current Trial (Cohorts A–C): Sernova’s current cohorts are focused on testing the safety and tolerability of transplanting donor islets (from cadaveric pancreases) into Sernova’s Cell Pouch device in T1D patients.
-
Future Direction (Post-Cohort C): Next, Sernova plans to launch a new clinical trial using iPSC-derived islet-like clusters, instead of relying on donor islets. This will be in collaboration with Evotec, a leading iPSC company.
-
Why iPSCs Matter: iPSC-derived islet-like clusters offer a renewable, potentially unlimited cell source for treating T1D, overcoming the limitations of donor availability. This aligns with Sernova’s goal of developing a scalable and widely accessible solution.
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called “KGF alternative- peptide (FGFR2b agonist)” which is functionally equivalent to recombinant keratinocyte growth factor (KGF). This product will be on the market beginning April 2025. [Read more…]
The Role of iPSCs in Farm Animals and Wildlife Conservation
Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have been potently transforming regenerative medicine, biotechnology, and conservation. Their ability to be reprogrammed from adult somatic cells unlocks new possibilities for enhancing farm animal reproduction, boosting disease resistance, and improving food quality, while also playing a pivotal role in wildlife conservation and species revival. However, their use raises ethical concerns, including the risks of genetic modification, unforeseen ecological consequences, and the moral dilemmas surrounding species de-extinction. [Read more…]
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 340
- Next Page »